J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
The group wants to improve on its own Welireg in a new phase 3 trial.
After a delay, the Alpha-3 study faces an April futility analysis.
Early data are coming with the KRAS G12D degrader ARV-806.
A first-in-human trial of PRT12396 starts next month.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
